Bleeding Endpoints News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Bleeding Endpoints. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Bleeding Endpoints Today - Breaking & Trending Today

Anthos Therapeutics' Novel Dual-Acting Factor XI/XIa Inhibitor, Abelacimab 150 mg, Demonstrated a 67% Reduction in the Primary Endpoint of Major or Clinically Relevant Non-Major Bleeding Compared with Rivaroxaban in Patients with Atrial Fibrillation

Published: November 12, 2023

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 12, 2023--

Source: eagletribune.com

Related Topics:

United StatesUnited KingdomColl CardiolThromb HaemostDan BloomfieldAnthos Therapeutics IncAmerican Heart AssociationHarvard Medical SchoolDrug AdministrationProgram In Cancer Associated ThrombosisBlackstone Life SciencesBroad InstituteCenters For DiseasePrimary EndpointClinically Relevant Non Major Bleeding ComparedAtrial FibrillationBusiness WireDisease ControlPrincipal InvestigatorGeneral CardiologyAssociate MemberAssociate ProfessorHarvard MedicalBleeding EndpointsChief Medical Officer